Top NYC, NY Analytics Companies With Best Stability & Growth (325)

Strong Revenue Growth: Reported results show sustained double‑digit top‑line expansion with a long streak of beat‑and‑raise quarters, and management has repeatedly lifted near‑term and multi‑year outlooks. Disclosures also highlight growth in large‑customer counts that supports continued scale.

Healthy Cash Flow: Company materials indicate operating and free cash flow expanded meaningfully alongside revenue, with increased guidance pointing to further cash generation. This trend suggests improving funding capacity for reinvestment while supporting resilience.

Innovation-Driven Growth: The platform’s AI‑forward roadmap (e.g., Athena by Zeta) is emphasized as a catalyst for adoption and efficiency, and third‑party evaluations cite strengths in AI‑enabled email capabilities. Management links these innovations to faster time‑to‑value and broader use across the marketing cloud.

Investor Backing & Capital Strength: Hex secured a $70M Series C in May 2025, bringing total funding to $172M and signaling substantial runway to scale. Participation from strategic investors, including Databricks Ventures in a prior round, underscores confidence in its model.

Strategic Partnerships: Hex was named the 2024 Snowflake Data Cloud Product AI Partner of the Year and emphasizes deep alignment within that ecosystem. These relationships elevate distribution and credibility within a leading data platform stack.

Innovation-Driven Growth: The company is advancing an AI-native platform, embedding AI across workflows and launching features like Threads and AI agents to accelerate insights. Its unified, AI-powered workspace aims to reduce fragmented toolchains and broaden impact across technical and non-technical users.

Strong Market Position & Advantage: Industry coverage and academic/government references portray Enverus as a category leader in energy data and analytics, with particularly deep strength in North American upstream and pervasive industry usage. A large installed base across oil and gas, power/renewables, and financial institutions supports breadth of use and entrenched workflows.

Investor Backing & Capital Strength: A definitive agreement for acquisition by a marquee private‑equity sponsor at a multi‑billion‑dollar value signals strong capital support and confidence in leadership and scale. Sponsor interest at this level is repeatedly cited as validation of category position.

Product Line Growth: A multi‑year sequence of acquisitions (advanced upstream analytics, solar plant design, AI‑powered procurement, interconnection studies automation, utility design automation) indicates steady expansion into adjacent workflows. Evidence of AI initiatives and broader power/renewables tooling shows the portfolio deepening beyond legacy upstream.

Strong Revenue Growth: Company communications indicate more than tripling ARR in 2025, attributed to expanding relationships with private‑equity sponsors and portfolio companies. This points to accelerating topline momentum in its targeted niche.

Market Expansion: Relocated and added offices in key hubs such as New York and Dallas, with additional locations like Toronto and Bengaluru also noted. These moves suggest a widening geographic footprint aligned to private‑equity centers.

Strategic Partnerships: Public materials highlight Snowflake Select Tier status and alliances with platforms like Dataiku and Google Cloud. Such ecosystem ties can enhance delivery credibility and route‑to‑market in data/AI deployments.

Investor Backing & Capital Strength: Advent International’s definitive agreement in August 2025 to acquire the company is presented as a strong signal of confidence in its leadership and growth prospects. The pending acquisition is framed around accelerating network expansion and product innovation.

Strong Market Position & Advantage: Independent and association coverage describes PatientPoint as operating the nation’s largest connected digital device network in tens of thousands of physician offices, bolstered by its 2021 combination with Outcome Health. Multiple sources characterize its leadership in terms of network size and advertiser reach.

Product Line Growth: Recent launches such as the Consumer Health Network and programmatic “Health Audiences” indicate expansion beyond traditional in‑office media into data‑driven activation. Partnerships and new offerings oriented to measurable outcomes suggest ongoing product momentum.

Investor Backing & Capital Strength: Multiple funding rounds, including a 2022 Series B and an additional raise in late 2024, indicate continued investor support and runway. These events suggest the company has access to capital to scale product and go‑to‑market efforts.

Product Line Growth: Successive launches and certifications (e.g., Signal alerts, Specialty Search, Insights Platform, medication history integration, and TEFCA-aligned offerings) point to a broadening portfolio beyond basic record retrieval. This cadence reflects ongoing investment in capabilities that activate and enrich clinical data.

Market Expansion: Connectivity spans all three nationwide exchange networks plus select state HIEs, with coverage claims that have increased meaningfully over time. These integrations imply widening national reach and utility across diverse customer segments.

Strong Revenue Growth: Results indicate sustained top-line expansion with record originations and receivables across both consumer and small‑business segments.

Profitability: Disclosures highlight materially higher earnings alongside strong net revenue margins and operating leverage from scalable analytics‑driven underwriting.

Strong Market Position & Advantage: Company materials and coverage describe a top‑tier position in online non‑prime consumer and SMB lending (via OnDeck), supported by multi‑brand scale and ongoing access to securitization markets.

Strong Market Position & Advantage: Analyst assessments from Everest Group, IDC MarketScape, and Forrester frequently place ZS in the Leader tier across life-sciences AI/analytics, digital services, HCP engagement, and R&D ITO. Feedback suggests this convergence of recent, scoped evaluations signals durable competitive standing in its core niches.

Market Expansion: ZS cites 13,000+ to 15,000+ professionals across 35–40+ offices and opened a new 50,000‑sq‑ft Hyderabad site, indicating expanded global delivery capacity. Capability-led acquisitions (e.g., Digital Additive; Torrent Consulting) further broaden geographic and service reach.

Innovation-Driven Growth: The firm launched a dedicated Platform & Products unit and is scaling ZAIDYN and Max.AI to embed AI and productized capabilities into client programs. Feedback suggests these moves position ZS for growth beyond services via AI-enabled, repeatable solutions.

Investor Backing & Capital Strength: A $25M Series B in mid-2024, including participation from major MLSs, indicates ample resources to invest in product, AI features, and go‑to‑market. This level of capital and strategic alignment supports its challenger trajectory.

Market Expansion: Selections by MLSs beyond NYC (e.g., Baldwin REALTORS in 2025) and a CRMLS beta/initiative starting in 2024 point to national expansion at a measured but real pace. Continued rollouts and feature updates through 2025–2026 reinforce active deployment in large markets.

Strategic Partnerships: Relationships with CRMLS, Stellar MLS, and REcolorado—including some as investors—demonstrate access to influential distribution channels. Such ties can accelerate adoption across multiple regions and validate the platform among MLS operators.

Strong Market Position & Advantage: Repeated leadership placement across multiple analyst evaluations and market-share analyses positions the company at the forefront of process mining/process intelligence, indicating strong execution and category influence. Consistent third‑party recognition and broad enterprise adoption signal reduced vendor risk for large-scale programs.

Investor Backing & Capital Strength: Recent late‑stage financing and access to sizable credit facilities indicate durable investor confidence and ample runway for continued product and go‑to‑market investment. Funding momentum and sustained decacorn‑level valuations reinforce balance‑sheet resilience.

Innovation-Driven Growth: Ongoing platform advances in AI‑driven process intelligence (e.g., process graphs and object‑centric mining) and high‑profile innovation awards suggest a strong product engine aligned with enterprise needs. Frequent feature releases and ecosystem integrations point to sustained R&D velocity.

Strategic Partnerships: Public announcements describe Palantir naming Northslope its first (and at the time only) Vanguard: Elite partner, with executive praise for helping customers win with AIP. This top-tier designation and co-marketing signal elevated standing and access within the Palantir ecosystem.

Strong Revenue Growth: Company communications state a breakout year with revenue growing nearly sevenfold alongside multiple production deployments across industries. Such momentum suggests rapid scaling of engagements on Palantir platforms.

Investor Backing & Capital Strength: A January 2026 release reports a $22M Series A led by investors with deep Palantir ties to scale engineering and platform capabilities. This capital raise indicates confidence in the business model and provides resources for expansion.

Strong Revenue Growth: Recent disclosures indicate revenue surpassed $1B in 2023 and reached around $1.1B in 2024 with double‑digit momentum into 1H‑2024, signaling clear top‑line acceleration. Headcount increases and growing community engagement further align with an expansion trajectory.

Strong Market Position & Advantage: Multiple consecutive Best in KLAS wins for Shared Care Records/HIE in Europe (2024–2026) and regional Acute Care EHR leadership (Asia/Oceania and France, 2026) highlight recognized leadership in core healthcare niches. Object‑oriented DBMS ranking strength reinforces a differentiated position for high‑throughput, multi‑model workloads.

Innovation-Driven Growth: New offerings (e.g., IntelliCare EHR, Payer Connector, HealthShare AI Assistant) and platform advancements (e.g., vector support, removal of historical DB size limits, partitioning) indicate sustained product velocity. These moves position the portfolio to capture demand in interoperability, AI, and large‑scale data workloads.

Investor Backing & Capital Strength: Recent funding rounds led by Goldman Sachs Alternatives and IVP are cited, supporting expansion of predictive AI, integrations, and skilled nursing investment. This capital base suggests the company is well-resourced to pursue growth plans.

Strategic Partnerships: Public updates highlight expanding integrations with major senior‑living EHRs (e.g., ALIS, Yardi, ECP, with PointClickCare and August Health timelines). These connections aim to position the platform alongside, rather than replacing, incumbent systems.

Market Expansion: Company communications report deployments across hundreds of communities in many states and portfolio‑wide rollouts with multi‑site operators. Stated plans include deeper moves into skilled nursing settings.

Strong Revenue Growth: Feedback suggests revenue and account volume expanded rapidly, with the company reporting multi‑fold increases in revenue, client count, and monthly accounts following its prior funding round. Company materials also indicate substantial debt serviced, signaling meaningful operating scale for a relatively new entrant.

Investor Backing & Capital Strength: Recent funding rounds, including a Series B, indicate continued investor support and resources to scale. Public statements frame this capital as enabling product development and go‑to‑market expansion with larger financial institutions.

Innovation-Driven Growth: An AI‑ and compliance‑first approach is presented as a core differentiator driving stronger recoveries and a more positive consumer experience. Feedback suggests this positioning has supported traction with banks, credit unions, fintechs, and debt buyers.

Strong Market Position & Advantage: Feedback suggests Collectors anchors category leadership through PSA in cards and PCGS in coins, reinforced by consolidating top grading brands under one parent. Liquidity advantages and record-setting auction outcomes for PCGS further entrench this position.

Strategic Partnerships: A 2024 commercial alignment with eBay integrated PSA’s grading and vaulting into marketplace flows, tightening end-to-end hobby workflows. Feedback suggests this enhances reach and convenience without needing to own the auction venue.

Market Expansion: PSA announced new U.S. hubs and opened/announced international facilities, aiming to boost throughput and shorten turnaround times. Growth in newer segments such as TCG and WNBA indicates expanding demand channels.

Strong Market Position & Advantage: Industry recognition from Inc., Deloitte, Ad Age, Digiday, Forbes, and Cynopsis, plus trust from major brands, agencies, and media companies, indicate a leadership stance in brand lift and cross‑media ad effectiveness. Deterministic, person‑level measurement and broad benchmarks further support a defensible position within its specialized niche.

Strategic Partnerships: Being named a preferred ad effectiveness partner by Warner Bros. Discovery and integrated across every DAX US audio campaign, alongside an ACR TV data integration with Inscape, demonstrate expanding channel coverage and distribution. These relationships extend adoption across TV/CTV and digital audio and signal enterprise‑level trust.

Innovation-Driven Growth: An award for Outcomes Lift (Digiday’s Best Measurement Solution) and the launch of a free self‑serve Brand Lift product showcase product velocity aimed at driving adoption. A privacy‑centric, identity‑based, cross‑platform approach positions offerings for a post‑cookie environment.

Strong Revenue Growth: Reported revenue accelerated sharply year over year with continued guidance for expansion, and quarterly results showed momentum across both diagnostics and data businesses. Total remaining contract value and rising spend among existing customers support durability.

Strategic Partnerships: Multi‑year collaborations with leading biopharma and health systems, along with an international joint venture, signal deep ecosystem integration. These agreements include substantial data licensing and model‑development components that reinforce platform adoption.

Strong Market Position & Advantage: An FDA‑approved NGS companion diagnostic, broad provider reach across many U.S. academic medical centers, and a scaled multimodal oncology dataset underpin positioning as a leader in AI‑enabled precision oncology. Public‑company status and expanding trial‑matching capabilities further reinforce this standing.